Bellicum Pharmaceuticals Return on Equity

Bellicum Pharmaceuticals (BLCM) currently reports a ROE of 80.69%. That is above the Healthcare sector average of 13.26%. Use the charts on this page to explore Bellicum Pharmaceuticals's ROE history and peer comparisons.

Bellicum Pharmaceuticals's ROE of 80.69% is higher than the Healthcare sector average of 13.26%. That is roughly 508.4% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Bellicum Pharmaceuticals's current 80.69% should be judged against Healthcare norms (sector average: 13.26%) and against BLCM's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 80.69%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.26%. From there, open related valuation or income-statement pages for Bellicum Pharmaceuticals, and consider following BLCM for alerts when major investors trade the stock.

Bellicum Pharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows 80.69% versus a sector average near 13.26%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BLCM with unrelated industries.